Breaking News

Mayne Acquires Branded Products

By Kristin Brooks | February 13, 2014

Expands business platform in North America with Forest purchase

Mayne Pharma USA has entered into an agreement to acquire branded pharmaceutical assets from Forest Laboratories for $12 million, with an upfront payment of $10 million, plus as much as $2 million payable quarterly based on future product sales. The products include pain drugs ESGIC, ESGIC PLUS, LORCET and LORCET PLUS brands and related assets. 
 
Additionally, Mayne had also recently acquired the branded ZEBUTAL trademark and related assets in the U.S. from Shionogi Inc., which had sales of $5 million in the 12 months ending December 2013.
 
“This agreement, combined with the recent acquisition from Shionogi, demonstrates Mayne Pharma’s commitment to growing its business platform within North America,” said. “Our company possesses the strength and agility to respond quickly when new and attractive business opportunities arise, and I fully expect that we will enter into more acquisitions and partnerships like these in the months to come.”
 
ESGIC tablets and capsules and ZEBUTAL capsules are used to treat tension headaches, and LORCET tablets are indicated for the relief of moderate to moderately severe pain. These products had IMS Health sales of $10 million in the 12 months ending December 2013. The total current annual market for these products, including their generic versions, is more than $400 million, according to IMS Health.

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Challenges in Global Biosimilar Development: A Regulatory Perspective

    Challenges in Global Biosimilar Development: A Regulatory Perspective

    Patricia Hurley, Joan Boren and Costantino Congiatu, PPD||June 2, 2015
    More than $60 billion worth of patents on biological products are expiring before 2020, representing a major opportunity for the pharmaceutical industry.

  • Single-Use Clarification System for High-Density Cell Cultures

    Single-Use Clarification System for High-Density Cell Cultures

    Tjebbe van der Meer, Sartorius Stedim Biotech||June 2, 2015
    Continuous improvements in growth media and cell line viability have resulted in increased biomass concentrations in biopharmaceutical production processes, making the downstream purification step more challenging. Body feed filtration has proven to be a successful method of solving similar issues in other industries. This robust technology is now available as a harvesting solution for biotechnology applications.